Tim Jenkins, partner at law firm Charles Russell Speechlys, spoke to C+D about the implications of Brexit at Avicenna's conference in Mauritius last week (June 1).
Mr Jenkins referred to findings of a poll conducted in collaboration with Avicenna on the C+D website May 10-19, which found that 40% of 107 respondents will vote to remain in the European Union in the referendum on June 23.
Read the full poll results here.
C+D has also spoken to a pharmacy owner from each country in the UK to gauge their views on Brexit. Read the results here.
We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information
The views and opinions discussed during this video news blog represent those of the speakers and not of Actavis UK Ltd Actavis
Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard
Adverse events can also be reported to Actavis on 01271 385257
* ‘Patient safety is Actavis’ primary concern and we encourage healthcare professionals and patients to report any adverse event which may occur in relation to an Actavis product. An adverse event includes reports of any side effect, product misuse, abuse or overdose, including inappropriate use by children or women who are pregnant or breast-feeding. It also includes reports of a product that was used for something other than the intended purpose or was ineffective, or was given with another medicine. Complaints relating to the product can also be reported.’